DANA-FARBER CANCER INSTITUTE

Palbociclib + standard therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer. No significant overall survival benefit observed among CDK4/6 inhibitor combinations in hormone receptor-positive/HER2-negative breast cancer. Patritumab deruxtecan showed similar efficacy to multiagent chemotherapy in high-risk hormone receptor-positive, HER2-negative breast cancer. Ciltacabtagene autoleucel achieved 100% complete response in high-risk smoldering multiple myeloma. Selinexor + ruxolitinib showed efficacy in myelofibrosis patients previously treated with ruxolitinib.

A trial suggests 'watch and wait' approach may be safe for low-risk DCIS breast cancer, potentially avoiding invasive treatments. Experts propose redefining DCIS as not cancer. Other breakthroughs include new drugs and weight-loss jabs for cancer prevention and treatment.

A study found CBD does not significantly reduce 'scanxiety' in metastatic breast cancer patients, but shows a calming effect and is non-toxic. Researchers suggest further exploration of CBD for cancer-related anxiety.

At the 2024 SABCS, advancements in breast cancer treatment were highlighted, focusing on SERDs, PROTACs, LYTACs, and biparatopic antibodies. SERDs like imlunestrant and fulvestrant degrade ER, with imlunestrant showing superior efficacy against mutated ER. PROTACs actively promote ER degradation, while LYTACs target surface proteins using lysosomes. Biparatopic antibodies enhance receptor internalization and degradation, offering potential for complex oncogenic drivers. These innovations aim to improve treatment efficacy for resistant and complex breast cancers.

Zejula-Jemperli combo showed 16.7% pCR and 44.4% RCB score of zero or 1 in BRCA-mutated ER+/HER2- breast cancer patients. Common severe side effects included rash, increased liver enzymes, and nausea.

Niraparib plus dostarlimab induced responses in BRCA-positive ER+/HER2- breast cancer patients, with a 16.7% pCR rate. Increased baseline sTILs associated with pathologic response. Further research on immunosuppressive tumor microenvironment needed.

Experts discuss strategies for dynamic clinical pathways, challenges in payer pathways, cost considerations, and the impact of accelerated drug approvals. Organizations like OneOncology, Dana-Farber Cancer Institute, and Florida Cancer Specialists emphasize participation, consistency, and adaptability in pathway development. Drug shortages and payer lag behind innovation are significant challenges. Effective communication, education, and cost considerations are crucial for pathway success.

BCRF investigators presented updates on breast cancer treatments, clinical trials, and BRCA2 variants at SABCS 2024. Key findings include potential new treatments, improved breast cancer care, and long-term survival benefits in younger women. BCRF's Health Equity Initiative highlighted disparities in breast cancer outcomes among Black women. Notable clinical trial updates and novel treatments were also discussed, with BCRF investigators receiving top honors for their contributions.

CBD did not significantly reduce scan-related anxiety compared to placebo, but it was safe and led to lower overall anxiety levels in patients with advanced breast cancer. The study suggests CBD's potential as an anxiety treatment, requiring further investigation.

Talquetamab, a bispecific antibody for relapsed/refractory multiple myeloma, presents unique toxicities like dysgeusia and skin issues but often yields strong responses. Dose modifications and holds are crucial, with some patients requiring reduced schedules. Toxicity duration varies, sometimes lingering for weeks. Experience suggests profound adverse events correlate with complete responses. Flexibility in dosing schedules exists, though data supporting extended intervals is limited. Premedications and preventive measures aim to mitigate toxicity.